Etiometry Achieves Key Milestones to Transform Critical Care, Continues Growth in 2025

Etiometry’s Critical Care Platform Delivers Better Patient Outcomes, Improved Economics for ICUs

BOSTON–(BUSINESS WIRE)–Etiometry, the leader in clinical decision support software for high-acuity units, celebrates a year of groundbreaking achievements in 2024 and shares its ambitious vision to transform critical care in the year ahead. In 2024, the company achieved significant milestones across scalability, innovation and clinical impact, thereby solidifying its role as an effective tool to drive better patient outcomes and improved economics within the most complex and expensive hospital units.

“2024 was a transformative year for Etiometry, driven by significant growth and adoption of our platform across ICUs, innovation and measurable clinical impact,” said Shane Cooke, CEO of Etiometry. “The data our platform uses and provides enables hospital leaders to easily recognize the tangible ways Etiometry supports better outcomes and streamlined workflows – ultimately saving and improving lives.”

Measurable Outcomes and Growing Adoption

Clinical data continued to highlight the platform’s impact, including a 36% reduction in ICU length of stay¹ and a 41% decrease in readmissions in the ICU.²​ Further evidence of the powerful impact of the Etiometry Platform was found at a new site that went live in November 2023 and in the ensuing year saw a 19.5% reduction in ICU length of stay as compared to prior to the deployment, along with an approximate 25% reduction in patient time on ventilation.³ Last year there were more than 2.5 million clinician interactions with Etiometry and logins into the platform reached 200,000 – a 50% increase from 2023, reflecting its growing adoption by care teams seeking reliable tools to improve patient outcomes, support newer clinicians with data-driven communications and enhance workflows to help standardize care.

Scaling for Impact Across Critical Care

Etiometry signed multiple enterprise agreements in 2024, extending its platform’s presence into more adult and pediatric ICUs, including prominent healthcare systems in the Midwest and Mountain regions of the U.S., as well as in international markets. These partnerships underscore the platform’s ability to standardize and individualize care, reducing variability and supporting clinicians in making data-driven decisions regarding both the escalation and de-escalation of care in the ICU setting.

Advancing Innovation with Strategic Partnerships

The company forged strategic alliances with two top 10 global med tech companies, paving the way for comprehensive solution bundles, including cardiogenic shock management. These collaborations enhance Etiometry’s platform, which already leverages FDA-cleared risk algorithms to provide near real-time insights for ICU teams to get ahead of patient deterioration.

Empowering Clinical Researchers

Etiometry launched ADK 2.0 in 2024, a groundbreaking Algorithm Development Kit designed to empower clinician researchers to develop, validate, and deploy custom algorithms for high-acuity care. Built on the same FDA-validated infrastructure that supports Etiometry’s platform, ADK 2.0 streamlines the path from research to clinical application, reinforcing Etiometry’s commitment to powering a “Learning Health System” within ICUs​.

Looking Ahead to 2025

Etiometry plans to build on its momentum with:

• Expansion of automated clinical pathways for acute respiratory distress syndrome (ARDS), cardiogenic shock, hemodynamic management after cardiac surgery, and ventilation weaning, further enhancing its capability to standardize care across ICUs.
• Development of new FDA-cleared algorithms and advancement of the utility of existing algorithms to address emerging challenges in critical care.
• Sustained focus on harnessing the platform to drive enhanced condition management across cardiogenic shock, hemodynamic management, respiratory failure and acute kidney injury (AKI).
• Deeper integration with electronic health records (EHR) systems to provide seamless workflows and better decision support.

“We’re in a great place to build on the incredible momentum we’ve established in 2024,” said Cooke. “The strides we’ve made set a strong foundation for 2025 to ensure the Etiometry platform becomes even more comprehensive, progressively integrative and increasingly informative—enabling care teams to navigate the complexities of critical care with confidence.”

About Etiometry

Founded in 2010, Etiometry is the leader in clinical decision-support software designed to help clinicians in the intensive care setting make data-based decisions regarding their patients’ care and treatment. The company’s technologies provide valuable clinical insight and analysis to support early recognition of subtle changes in patients’ conditions to avoid complications and speed recovery. Etiometry has nine FDA clearances and four Health Canada approvals and CE markings. Etiometry is utilized by some of the world’s top academic medical centers as well as leading children’s hospitals ranked by US News and World Report and Newsweek. Etiometry is committed to improving patient outcomes, increasing clinical efficiency, and lowering the cost of care through the more effective use of data. To learn more, visit www.etiometry.com.

The Etiometry Platform is an end-to-end data management software solution for the collection, analysis, visualization, and archiving of ICU clinical data. It is designed to facilitate the use of all available data to support the anticipation and management of the dynamic condition of patients requiring intensive care. To learn more, visit www.etiometry.com.

Citations: 1. Salvin et al, AHA ‘17 2. Gaies et al. Circulation ’23. 3. Etiometry data on file.

Contacts

Media:
Hyedi Nelson

Bellmont Partners

Hyedi@bellmontpartners.com
651-757-7054